{"filing":{"accession_number":"0001345099-26-000072","cik":"0001345099","ticker":"MEOBF","company_name":"MESOBLAST LTD","form":"6-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"form6-kxpressreleasecoverf.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509926000072/form6-kxpressreleasecoverf.htm"},"events":[{"id":22127,"run_id":19996,"accession_number":"0001345099-26-000072","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This exhibit is a press release announcing Mesoblast's financial results and operational highlights for the quarter and full year ended June 30, 2026. It discloses Ryoncil® net revenues of US$36M for Q4 and US$115M for the first full year post-FDA approval, along with operating cash spend and cash position. The document includes the Appendix 4C quarterly cash flow report, which is the standard periodic financial disclosure for ASX-listed entities. While the exhibit bundles operational updates (clinical trial progress, regulatory clearances, CAR technology acquisition), the primary disclosure is the financial results and cash flow statement, making this an earnings release for the fiscal year and quarter ended June 30, 2026.","company_name":"MESOBLAST LTD","ticker":"MEOBF","filing_date":"2026-07-30","form":"6-K","submitted_at":null,"items":[{"id":21981,"accession_number":"0001345099-26-000072","item_number":"EX-99.1","item_title":"exhibit991activitystatem.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This exhibit is a press release announcing Mesoblast's financial results and operational highlights for the quarter and full year ended June 30, 2026. It discloses Ryoncil® net revenues of US$36M for Q4 and US$115M for the first full year post-FDA approval, along with operating cash spend and cash position. The document includes the Appendix 4C quarterly cash flow report, which is the standard periodic financial disclosure for ASX-listed entities. While the exhibit bundles operational updates (clinical trial progress, regulatory clearances, CAR technology acquisition), the primary disclosure is the financial results and cash flow statement, making this an earnings release for the fiscal year and quarter ended June 30, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:01:06.152277+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21981,"accession_number":"0001345099-26-000072","item_number":"EX-99.1","item_title":"exhibit991activitystatem.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This exhibit is a press release announcing Mesoblast's financial results and operational highlights for the quarter and full year ended June 30, 2026. It discloses Ryoncil® net revenues of US$36M for Q4 and US$115M for the first full year post-FDA approval, along with operating cash spend and cash position. The document includes the Appendix 4C quarterly cash flow report, which is the standard periodic financial disclosure for ASX-listed entities. While the exhibit bundles operational updates (clinical trial progress, regulatory clearances, CAR technology acquisition), the primary disclosure is the financial results and cash flow statement, making this an earnings release for the fiscal year and quarter ended June 30, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:01:06.152277+00:00","company_name":"MESOBLAST LTD","ticker":"MEOBF","filing_date":"2026-07-30"}]}